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Abstract
Background: Melatonin is often used as a sleeping aid in elderly adults. As previous studies suggest a protective
role of melatonin against osteoporosis, it is important to document its safety. Treatment should not cause any
hangover effect that could potentially lead to falls and fractures. We therefore aimed to evaluate the effect of
melatonin on balance- and muscle function.
Methods and patients: In a double-blind placebo-controlled study, we randomized 81 postmenopausal women
with osteopenia to receive 1 or 3 mg melatonin, or placebo nightly for 12 months. Postural balance as well as
muscle function was measured. In addition, we assessed quality of life and sleep at baseline and after 12 months
treatment.
Results: Compared to placebo, one-year treatment with melatonin did not affect postural balance or risk of falls.
Furthermore, no significant changes between groups were observed in muscle strength in neither upper- nor lower
extremities. Treatment did not affect quality of life or sleep. However, in the subgroup of women with sleep
disturbances at baseline, a trend towards an improved sleep quality was seen (p = 0.08).
Conclusion: Treatment with melatonin is safe in postmenopausal women with osteopenia. There is no hangover
effect affecting balance- and muscle function following the intake of melatonin. In women with a good quality of
sleep, melatonin has no effect, however in poor quality of sleep, small doses of melatonin trended towards
improving the quality.
Trial registration: (# NCT01690000)
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Introduction
Melatonin in known for its regulation of circadian rhythm.
It is produced in the pineal gland and is stimulated by
darkness while inhibited by light [1]. In humans, the
production decreases by age [2], and treatment with mela-
tonin may be used as a sleeping aid in elderly people.
In some European countries and the United States,
small doses of melatonin are considered a dietary supple-
ment. In other European countries, including Denmark,
melatonin is still a prescription drug against primary in-
somnia recommended to patients >55 years of age in a
dose of 2 mg taken at bedtime. Despite an unknown
prevalence of the usage of melatonin, there is an increas-
ing interest in melatonin in addition to its effects as a
sleeping aid. Melatonin has also shown to be of import-
ance for a number of other physiological functions as ex-
perimental and clinical studies have shown a stimulation
of the immune system [3], protection against aging [4],
cancer [5] and hypertension [6]. Moreover, melatonin may
be of importance to bone, as it has been shown to upregu-
late osteoprotegerin (OPG) and suppress receptor activa-
tor of NK-κB ligand (RANKL) [7, 8]. Furthermore, studies
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have demonstrated an increased stimulation of the os-
teoblastic cell lineage with suppression of peroxisome
proliferator-activated receptor gamma (PPARγ) and en-
hanced expression of bone morphogenic proteins (BMPs)
2 and 4 [9, 10]. In response to treatment with melatonin, a
recent randomized, placebo-controlled study by our group
demonstrated an increase in arealBMD in the femoral
neck as assessed by DXA, and in volumetricBMD in the
lunbar spine as assessed by quantitative computed tomog-
raphy (QCT) in postmenopausal women with osteopenia
(low bone mass with a T-score between -1 and -2.5 [11,
12]).
In general, melatonin is considered a safe treatment
option in the elderly. However, if melatonin is going to be
used for long term prevention and treatment of osteopor-
osis (low bone mass with a T-score < −2.5 [11]), it is of
specific importance to document its safety. Treatment
should not cause any hangover effect (e.g. dizziness or
drowsiness) resulting in decreased postural balance and
muscle strength that could potentially lead to falls and
fractures.
Therefore, as a part of our double-blind randomized
placebo-controlled trial on the effect of melatonin in
postmenopausal women with osteopenia [12], we evalu-
ated the effects of one-year treatment with melatonin in
a daily dose of 1 or 3 mg administered at bedtime on
postural balance and muscle function. Furthermore,
quality of life and sleep were assessed to see if any




We performed a double-blinded randomized placebo-
controlled study. Inclusion criteria were postmenopausal
women diagnosed with osteopenia (T-score −1 to–2.5 in
either hip or spine). There were no requirements to qual-
ity of sleep prior to entering the study. We invited 202
women, and 150 responded positively, hereof 65 were
excluded due to exclusions criteria or declining participa-
tion after further information. Ultimately, 85 women ac-
cepted the invitation, and the first 81 (aged 56–73 years)
to accept were randomised to treatment or placebo [12].
The participants were recruited by letter from our out-
patient clinic as all women were already diagnosed with
osteopenia. The exclusions criteria were, in brief women
with known medical conditions affecting the bone. This
included p-creatinine >120 μmol/L, P-ionized calcium
>1.32 mmol/L, intestinal malabsorption, impaired lever
function, smokers and users of drugs with effects on
calcium homeostasis. Furthermore, users of antiresorp-
tives, hormone replacement therapy and alcohol abusers
(>14 units/wk) were also excluded [12]. The patients were
randomized to receiving either 1 or 3 mg of melatonin, or
identical placebo daily for 12 months. The tablets were
given orally at bedtime. Melatonin as well as identical
placebo was manufactured by Skanderborg Pharmacy. As
previously mentioned, melatonin is a prescription drug in
several European countries recommended in doses of
2 mg. Therefore, to ensure no discomfort among the study
subjects, besides the reports from the use of 2 mg, we
chose doses close hereto. Furthermore, all participants
received a daily supplement of 800 mg calcium and 20 μg
vitamin D3. All participants provided informed consent
prior to participation in the study. The study was per-
formed in accordance with the Helsinki II declaration.
The study was approved by the local ethic committee
of central Denmark (#M2012-252-12), the Danish Na-
tional Board of Health (EudraCt nr 2011-004670-28),
the Danish Data Protecting Agency, and registered by
ClinicalTrials.gov (# NCT01690000). The Good Clinical
Practice (GCP) unit at Aarhus University Hospital,
Denmark monitored the project. All study subjects pro-
vided a written consent before entering the study.
Postural stability
We assessed postural stability by using a stadiometer
(Good Balance Platform System™, Metitur Ltd. Finland) to
measure body sway. The stadiometer is a triangular
platform used to convert shifts in weight to digital data to
obtain an assessment of maintenance of balance. The
platform reports length (millimetres) and speed (milli-
metres/second) of the sway in medio-lateral and anterior-
posterior direction. The interclass correlation coefficient
was 0.87-0.96 [13].
Under four settings, we measured postural stability:
1. Normal standing eyes open (EO). The participant is
placed with the feet next to each other with 20 cm
apart. The arms are in relaxed position hanging
freely at each side and with a fixed gaze on a marked
spot in eye level.
2. Normal standing eyes closed (EC). The participant is
placed in the same position as the previous exercise
but with the eyes closed.
3. Semi-tandem. The heel on the foot on the non-
dominant hand side is placed alongside the big toe
on the dominant hand’s side. Arms and gaze are in
accordance with the first measure.
4. Tandem. The non-dominant hand’s foot is placed in
front of the dominant hand’s foot. Eyes and arms as
described in measure 1.
The exercises were performed barefoot. The duration of
each exercise was 20 second and repeated three times.
Data are presented as the velocity moment (VM mm2/s),
which is calculated as 90 % of the product of the actual
distance of movement in the medio-lateral and anterior-
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posterior direction from the center of pressure per second.
We adjusted for the effect of body height, and vertical
location of the center of body mass by Scaled Velocity
Moment (SVM) = (VM/(height in cm)2) × 1802. The best
measure for each exercise was chosen for further analysis
(i.e. the lowest VM).
Muscle strength
The maximum voluntary isometric muscle strength at the
upper and lower extremity was measured with an adjust-
able dynamometer chair connected to a computer (Good
Strength™, Metitur Ltd, Finland) [14]. The device has
demonstrated high reliability coefficients (0.88-0.96) for
both upper and lower extremities [15]. Recording time of
each measure was 5 seconds. Upper extremity strength
was assessed by hand grip, and elbow flexion and exten-
sion with the elbow in 90 dgr flexion from neutral pos-
ition. Knee extension and flexion were measured in a 60
dgr and 90 dgr angle from fully extended leg. All measure-
ments were performed while sitting in the chair. The
trunk was supported with three belts to minimize transfer
of strength from other sites. The excises were performed
on the dominant hand’s side and repeated three times with
a 30-second break between the recordings. The best per-
formance was chosen for further analysis. Maximum
strength was measured in newton (N).
Quality of life
We used a Danish versions of the Short Form question-
naire 36 version 2 (SF-36) and WHO-Five Well Being
Index (WHO-5) to assesses quality of life and well-
being. The SF-36 questionnaire consist of 36 questions
categorized into 8 subdomains describing physical func-
tioning (PF), role-physical (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role-
emotional (RE), and mental health (MH). The subdo-
mains are summed up to a mental component score
(MCS) and a physical component score (PCS) and can
be calculated using norm-based values according to the
user’s manual [16].
The Who-5 index consists of five questions, and an-
swers are scored from 0 (worst) to 5 (best). The scores
are summed up, multiplied by four, and presented as a
total percentage from 0–100. A well-being score below
50 % indicates a depressive affection [17].
Both questionnaires are well used and validated [18].
Quality of sleep
A Danish version of Pittsburgh Sleep Quality Index
(PSQI) [19] was used to assess the quality of sleep. The
questionnaire comprises of 21 questions generated into
seven components: Subjective sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep distur-
bances, use of sleep medication and daytime dysfunction.
The subdomains are summed up to a global score; scoring
five or below indicating a good quality of sleep while a
score above five is associated with a poor quality of sleep.
Physical Activity Scale (PAS)
We assessed physical activity by a Danish version of the
Physical Activity Scale (PAS) questionnaire in which the
participants reported time spend on sports, work, and leis-
ure time on an average weekday [20]. The questionnaire is
organized into nine questions regarding activity corre-
sponding to a known metabolic equivalents (MET, 1 kcl/
kg/h) level ranging from low activity to high intensity
activity: sleep (0.9 MET), TV-viewing/reading (1.0 MET),
sitting/working (1.5 METs), standing up (2.0 METs), light
work (3.0 METs), light to moderate activity (4.0 METs)
moderate activity (5.0 METs), moderate to high activity
(6.0 METs) and high intensity activity (7 METs) [20]. Each
question is imaged and described by examples of the
specific activity. A total MET-score was calculated as
minutes and hours spent on each activity multiplied by
the assigned MET value, and adding the nine MET activity
levels together.
General questionnaire
Our participants filled out a questionnaire regarding life
style including question about use of medication, previ-
ous fractures, and daily intake of dietary calcium.
Blood pressure
In calm settings, and with the study subject in a resting
state, we measured blood pressure and heart rate. For
the purpose, we used an automatically inflated brachial
cuff connected to an oscillometric reading system meas-
uring heart rate and blood pressure.
Clinical visits
Questionnaires, and balance- and muscle function tests
were performed at baseline and after 12 months treat-
ment. At baseline and after 3, 6, 9, and 12 months of treat-
ment the women came for a clinical visit answering
question about falls, fractures and adverse advents, and to
have their blood pressure measured. Balance- and muscle
function were assessed during the morning or afternoon
while all clinical visits were carried out in the morning.
The same investigator conducted all visits and supervised
all exercises to ensure a uniform instruction to all study
subjects.
Statistics
As this is a part of our randomized placebo-controlled
study on women with osteopenia, sample size was calcu-
lated on the basis of our main outcome with a predicted
1.5 % change in BMD between the melatonin and pla-
cebo group. This ultimately led to a total of 72 study
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subjects (80 % statistical power and 5 % significance). In
the present study, to show a 10 % change in knee exten-
sion 60° in healthy women (mean force 393 N, SD ±53 N)
[21] a total number of 30 study subjects in each groups
was required (80 % statistical power, 5 % significance).
We analysed data using with the intention to treat
approach as results from all randomized subjects with a
follow-up value were included according to the treatment
allocation. Differences between groups were tested by the
Student’s t test or Wilcoxon Rank-Sum test, as appropri-
ate. Serial changes of blood pressure values were analysed
by variance for repeated measures (ANOVA). Interaction
between group and time (gr. vs. time) were studied in
order to determine whether treatment affected changes
blood pressure differentially during the study. Area under
the curve (AUC) was calculated in order to assess differ-
ences between groups in average blood pressure.
We used Pearson Chi-square or Fischer’s Exact Test
for categorical variable. Correlations between variables
were tested by bivariate correlation analyses (r). Data are
presented as mean with 95 % confidence interval (CI) or
median with 25–75 % interquartile range (IQR). The
significant level was p < 0.05. We used IBM SPSS Statis-
tics 21 to perform all calculations.
Results
Forty-one women were allocated to placebo, while 40
were allocated to either 1 or 3 mg melatonin. Descriptive
data are shown in Table 1. In general, randomization
was well balanced with no significant differences be-
tween groups.
During our one-year trial including 81 women, we re-
corded in total 36 adverse events (AE) and 12 serious
adverse events (SAE). The events occurred at equal fre-
quency in both groups. In all, we recorded two falls in
each group. Two of the falls (one in each group) were
caused by snow covering irregularities in the pavement.
The other two falls were caused by sightseeing as the
women overlooked irregularities in the pavement.
Seventy-two women completed the study. Of the nine
women dropping out during the trial, five were in the
placebo group while four were in the melatonin group
[12]. The treatment was well-tolerated and only 16
(40 %) of the women in the melatonin group guessed
their randomization compared with 29 (74 %) in the pla-
cebo group. The few adverse events and the good-
tolerance was the reason why they believed to receive
placebo in any of the experimental settings.
At baseline the placebo group had a reduced postural
stability by normal standing EO compared to the mela-
tonin group (Table 2). However, 12 months of treatment
with melatonin did not affect postural stability compared
with placebo.
Table 3 shows the results of the muscle strength mea-
sures. No significant differences between groups were
present at baseline. One-year treatment with melatonin
did not affect upper or lower extremity performance in
any of the groups.
Stratifying for doses of melatonin did not change the
results in either balance- nor muscle function tests (data
not shown).
Table 4 shows the results of the questionnaire data. Ac-
cording to quality of sleep index (PSQI), both groups had
a good quality of sleep at baseline (5 in placebo group vs.
4.5 in melatonin group). No significant changes between
groups were found in response to treatment. Restricting
Table 1 Descriptive data at baseline. Mean (±standard deviation) or median (25–75 % interquartile range)
Placebo N = 41 Melatonin N = 40 P-value
Age, years 62.9 (±4.7) 62.4 (±3.5) 0.46
BMI (kg/m2) 24.9 (21.4;26.6) 23.6 (21.3;27.5) 0.38
Weight (kg) 66.6 (60.0;76.0) 65.0 (58.3;75.5) 0.58
Systolic blood pressure (mmHg) 143 (130;149) 138 (128;144) 0.15
Diastolic blood pressure (mmHg) 83 (77;92) 85 (76;91) 0.76
Heart rate 68 (64;75) 70 (64;76) 0.94
Dietary calcium (mg/d) 950 (800;1125) 975 (800;1100) 0.66
Previous fracture after the age of 55 years, (N %) 6 (15 %) 8 (20 %) 0.57
Prescribed medication, N (%) 21 (51 %) 20 (50 %) 0.99
Simvstatin, N (%) 5 (12 %) 3 (8 %) 0.71
Antidepressives, N (%) 2 (5 %) 2 (5 %) 0.99
Benodiazepines, N (%) 1 (2 %) 0 0.99
Antihypertensives, N (%) 6 (14 %) 4 (10 %) 0.74
Levothyroxine, N (%) 1 (2 %) 1 (2 %) 0.99
Pittsburgh Sleep Quality Index > 5 20 (49 %) 9 (23 %) 0.02
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analyses to study subjects with a score above normal
range, i.e. associated with a poor quality sleep/insomnia,
this was reported more frequently by women in the pla-
cebo group compared with women in the melatonin
group (49 vs. 23 %, respectively, p = 0.02) (Table 1). In
response to treatment, the women in the melatonin group
rated with insomnia reduced their score by −37.5 % (IQR:
−64.5;−15.5) compared with −13.3 % (IQR: −32.1;9.4) in
the placebo group (p = 0.08 for between group changes).
In the subgroup of women with insomnia, 58 % of the
women guessed their randomization i.e. 86 % in the pla-
cebo group and 14 % in the melatonin group (p = 0.01).
The percentage change in PSQI-score did not differ in
women believing to receive melatonin compared to
those believing to receive placebo (data not shown).
There were no differences in quality of life between
groups in any of the subdomains (data not shown), MCS
or PCS at baseline or at follow up. In all the subdomains
as well as MCS and PCS, both groups scored within the
normal range compared to norm-based values. Who-5
index did not change over time between the groups
(Table 4). A significant inverse correlation was present
between changes in PCS and changes in PSQI (r = −0.36,
p < 0.01) meaning that the better PCS, the better quality of
sleep. No correlation was present between PSQI and other
physical parameters such as PAS, muscle and balance
function (data not shown). No changes between groups
were observed when assessing physical activity (PAS).
Heart rate and blood pressure did not differ between
groups at baseline. Compared with placebo, melatonin
caused a non-significantly decrease in systolic (5 mmHg,
p = 0.12) and diastolic (2 mmHg, p = 0.40) blood pressure
(Fig. 1). Heart rate did not change in response to treat-
ment (data not shown).
Discussion
In the present study we investigated the effects of one-
year treatment with melatonin on balance- and muscle
function as well as physical and mental well-being in post-
menopausal women with osteopenia. Our study did not
raise safety concerns regarding reduced postural balance-
or muscle function. Furthermore, in postmenopausal
women with a normal sleep quality, treatment with low
doses of melatonin did not affect quality of life or sleep. In
the subgroup of people with insomnia there was, however,
a borderline significant improvement in quality of sleep in
the melatonin group compared to placebo.
To the best of our knowledge this is the first study to
evaluate the effect of longer term treatment with small
doses of melatonin on balance- and muscle function in
postmenopausal women. Melatonin is commonly used
as a sleep aid in the elderly. As melatonin increased
bone mineral density [12] through previously mentioned
Table 2 Postural balance (scaled velocity moment [m2/s]).
Baseline and percentages changes after 12 months of treatment
with melatonin or placebo (median with 25–75 % interquartile
range
Baseline (m2/s) P-value Changes after
12 months (%)
P-value*
Normal standing, eyes open 0.04 0.11
Placebo 4.1 (2.9;6.4) −10.98 (−30.39;19.00)
Melatonin 3.3 (2.7;4.1) 6.30 (−22.83;43.43)
Normal standing, eyes closed 0.31 0.29
Placebo 5.7 (3.6;8.5) −7.79 (−39.72;33.31)
Melatonin 4.7 (3.4; 6.7) 4.06 (−24.17;50.00)
Semi tandem 0.58 0.67
Placebo 20.4 (15.6;33.1) −4.97 (−33.98;29.42)
Melatonin 20.5 (16.4; 28.7) −15.60 (−26.79;23.33)
Tandem 0.48 0.55
Placebo 48.7 (34.1;63.3) −4.00 (−38.45;48.70)
Melatonin 43.3 (29.0; 73.3) 2.10 (−26.27;46.77)
Significance is shown in bold
*Percentages change between groups
Table 3 Maximum voluntary muscle strength (Newton [N]).
Baseline data and percentage change after 12 months of
treatment according to group allocation. Median with








Hand grip 0.79 0.58
Placebo 287 (257;311) −0.18 (−7.02;6.78)
Melatonin 281 (244;333) −0.75 (−10.40;7.59)
Elbow extension 0.23 0.74
Placebo 116 (98;138) 6.21 (1.23;12.85)
Melatonin 111 (92;121) 5.20 (−3.51;15.28)
Elbow flexion 0.18 0.37
Placebo 178 (156;192) 1.95 (−6.77;10.75)
Melatonin 165 (152;185) −1.45 (−9.12;6.91)
Knee extension 90° 0.67 0.99
Placebo 309 (278;377) 0.33 (−2.68;5.44)
Melatonin 312 (275;357) 0.55 (−6.66;11.26)
Knee flexion 90° 0.40 0.93
Placebo 160 (137;177) 0.26 (−7.13;16.89)
Melatonin 153 (121;177) 0.00 (−6.09;13.79)
Knee extension 60° 0.26 0.33
Placebo 384 (326;433) 0.76 (−4.08;4.16)
Melatonin 370 (313;410) 1.73 (−5.94;10.49)
Knee flexion 60° 0.44 0.54
Placebo 169 (139;203) 4.31 (−9.61;22.58)
Melatonin 163 (138;182) 0.99 (−2.53;9.66)
*Significant changes between groups
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possible mechanisms, it may also in the future play a
role in the prevention and treatment of osteoporosis. It
is therefore of importance to rule out any long term
adverse effects that may increase the risk of falls and
fractures. The manufacture of 2 mg melatonin describes
the side effects in terms of hangover (dizziness and
sleepiness during the day) as events occurring in 0.1–
1 % of the patients [22]. The half-life of melatonin is
dependent on the composition of the drug varying from
app. 30 min to four hours, and may be affected by e.g.
fasting state [22–25]. Administered just before bedtime,
melatonin should be eliminated in the morning. How-
ever, as described by the manufactures of 2 mg mela-
tonin, hangover during the day may still occur, which is
probably caused by intersubject viability.
In previous studies, discrepant results have been re-
ported on the effects of melatonin on balance perform-
ance. In one study [26], an oral intake of 10 mg of
melatonin was found to impair postural stability, whereas
Otmani et al. [27] reported no detrimental effects of 2 mg
short term treatment of melatonin on postural balance.
Furthermore, the hangover effect of melatonin has previ-
ously been examined in relation to muscle strength in
young adults showing no alteration in response to a single
dose of 5 mg melatonin [28, 29]. In the present study we
evaluated the effect of melatonin in response to one-year
treatment. A potential adaption to side effects causing no
changes in balance and muscle function cannot be com-
pletely ruled out. However, contradicting this postulate,
we reported an equal frequency of falls in the groups
throughout the trial. Furthermore, to avoid learning effect
to the exercises, it is of rational not to repeat the measure-
ments until one-year of treatment.
In a previous study by Kotlarczyk et al. [30], the authors
investigated the effect of 3 mg melatonin/d for 6 months
in 18 healthy perimenopausal women. In line with our
results, no effect of melatonin was seen in relation to the
average quality of sleep. This is most likely explained by
the fact that both studies comprised of subjects without
known sleep disturbances, and the results are further sup-
porting the findings by other investigators [31]. It is, how-
ever, well known that melatonin has a positive effect on
sleep in patients with insomnia [32, 33]. Similar to these
results we did find a trend towards a positive effect of
melatonin on quality of sleep in the subgroup of people
with pre-exiting poor quality of sleep. The lack of statis-
tical significance is most likely explained by a too low stat-
istical power.
Concerning the self-rated quality of life questionnaires,
we conclude that melatonin does not affect the outcome
measures negatively. Our results are in accordance with
Kotlarczyk et al. [30] who demonstrated a safe use of
melatonin with no significant changes in domains, ex-
cept physical, as assessed by Menopause-Specific quality
Table 4 Quality of life, sleep quality, and physical activity. Baseline data and changes (%) in response to 12 months of treatment
with melatonin or placebo. Median scores with 25–75 % interquartile range
Baseline P-value Changes after 12 months (%) P-value*
Physical component score 0.69 0.16
Placebo 54.9 (48.2;56.9) 1.80 (−3.79;7.11)
Melatonin 54.7 (50.9;57.4) −0.30 (−4.00;4.83)
Mental component score 0.12 0.94
Placebo 56.6 (51.8;59.0) −0.78 (−5.88;4.47)
Melatonin 58.0 (55.6;59.5) −0.34 (−6.13;4.12)
WHO-5 Well-being Index 0.63 0.27
Placebo 80.0 (72.0;84.0) 0.00 (−9.52;5.00)
Melatonin 80.0 (73.0;84.0) 0.00 (−5.00;5.56)
Pittsburgh Sleep Quality Index 0.36 0.31
Placebo 5.0 (2.0;8.5) 0.00 (−32.14;38.33)
Melatonin 4.5 (3.0;5.0) 0.00 (−41.11;28.79)
Pittsburgh Sleep Quality Index > 5 0.47 0.08
Placebo, N = 20 8.5 (6.0;9.8) −13.3 (−32.1;9.4)
Meltonin, N = 9 8.0 (6.0;8.5) −37.5 (−64.5;-15.5)
Physical activity scalea 0.17 0.43
Placebo 43.8 (37.4;48.7) −0.16 (−8.46;8.29)
Melatonin 46.0 (40.9;51.3) −2.27 (−13.84;10.07)
*Percentage change between groups
aMetabolic equivalent (MET) score for 24 hours
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of life (MENQOL) questionnaire. The physical domain
increased in the study in response to melatonin. Our re-
sults showed a significantly inverse correlation between
the physical component score (PCS) and quality of sleep
indicating that the better the physical score, the better
the sleep. Although an effect of melatonin in relation to
quality of life has previously been shown in patients with
known sleep disturbances [33] our study consisted of
healthy women with a good quality of life and an in-
crease was not expected.
There have previously been demonstrated a reduction in
nocturnal systolic and diastolic blood pressure after
nightly therapeutic doses of 2–3 mg melatonin [6, 34, 35].
However, it line with previous results [30], we did not
observe significant effects of melatonin on blood pressure.
This may be explained by the fact that we did not measure
blood pressure during night after ingestion of melatonin.
There are several strengths to the study including its
design as a double-blind randomized placebo- controlled
trial. Furthermore, as to evaluate the effect of melatonin,
the study subjects were in the relevant age group. There
are however, also limitations to the study, as the women
did not suffer from sleep disturbances prior to entering
the study. However, a positive effect was not anticipated
as our primary goal was to establish the safety aspects of
longer term treatment with melatonin.
In conclusion, melatonin in a daily dose of 1 or 3 mg
is safe to use in postmenopausal women with osteope-
nia. There is no long term hangover effect causing a
reduction in balance- and muscle function or quality of
life. In women with poor quality of sleep, small doses of
melatonin trended towards improving quality of sleep.
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